Why the study?
Does Myocardial Extracellular Volume Fraction (ECV) improve prognostic assessment for heart failure outcomes beyond Late Gadolinium Enhancement (LGE)?
Does Myocardial Extracellular Volume Fraction (ECV) improve prognostic assessment for heart failure outcomes beyond Late Gadolinium Enhancement (LGE)?
Myocardial Extracellular Volume Fraction (ECV) provides prognostic value for heart failure outcomes independent of and synergistic with replacement fibrosis (LGE).
May refine HF prognostication beyond LGE; leaves open need for prospective validation before practice change.
ECV measures of diffuse myocardial fibrosis were associated with HF outcomes, despite exclusion of replacement fibrosis segments from their derivation and even among patients without any scar. ECV may have a synergistic role with LGE in HF risk assessment.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2019) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More on Cardiac MRIMore from Circulation Cardiovascular Imaging